Orforglipron
InvestigationalAlso known as: LY3502970, OWL833
The first oral small-molecule (non-peptide) GLP-1 receptor agonist. NDA submitted to FDA. ATTAIN trials showed 12.4% weight loss at 72 weeks. No food/water restrictions unlike oral semaglutide. Phase 3 data in 9,000+ patients.
Research Statistics
Eli Lilly oral non-peptide GLP-1 agonist with Phase 3 global trials and established GLP-1R mechanism; multinational program with strong human data and FDA NDA submission anticipated.
Research Dossier
Overview
What is Orforglipron and what does the research say?
Mechanism of Action
Orforglipron is a first-in-class oral small-molecule GLP-1 receptor agonist with robust Phase 3 clinical evidence.
How It Works (Simplified)
Orforglipron achieves similar metabolic effects to injectable GLP-1 drugs, but in a convenient oral pill:
Activates GLP-1 receptors with strong cAMP signaling but minimal beta-arrestin recruitment, potentially reducing receptor desensitization.
Acts on hypothalamic GLP-1 receptors to reduce hunger signals, leading to decreased caloric intake and sustained weight loss.
Enhances glucose-dependent insulin secretion from pancreatic beta cells, improving blood sugar control without hypoglycemia risk.
Unlike peptide GLP-1 drugs, this small molecule survives stomach acid and absorbs efficiently without food restrictions.
Scientific Pathways
GLP-1 Receptor Activation (Biased Signaling)
Orforglipron → GLP-1R transmembrane binding → Gs protein coupling → cAMP accumulation
↓
Reduced beta-arrestin → Sustained receptor activityMetabolic Effects (Weight & Glucose)
GLP-1R activation → Hypothalamus (↓appetite) + Pancreas (↑insulin) + Stomach (↓emptying)Key Research: Kawai T et al. (PNAS 2020) elucidated the structural basis for non-peptide GLP-1R activation. PMID:32747553
Important Limitations
- Long-term cardiovascular outcomes data still pending (ACHIEVE-CVOT ongoing)
- Not yet FDA-approved (NDA submitted, Priority Review granted)
- GI side effects occur in 25-35% of patients (similar to injectable GLP-1 class)
- Daily dosing required (unlike weekly injectable alternatives)
- Optimal use in combination with lifestyle modifications
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial titration period. GI side effects (nausea, vomiting, diarrhea) most common during dose escalation. Appetite reduction typically begins within first weeks.
Progressive weight loss observed. Phase 2 data showed approximately 5-7% weight loss by week 12 at higher doses. Glycemic improvements evident in diabetic patients.
Continued weight loss trajectory. Phase 2 showed 11.6% weight loss at 36 weeks with 36mg dose. GI tolerability generally improves after initial weeks.
Phase 3 ATTAIN trials demonstrated 12.4% weight loss at 72 weeks in obesity (ATTAIN-1) and 9.6% in obesity with T2D (ATTAIN-2). Sustained metabolic benefits observed.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Orforglipron product quality
Good Signs (5 indicators)
Warning Signs (4 indicators)
Bad Signs (5 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Orforglipron with other peptides. Based on published research and mechanistic considerations.
5-Amino-1mq
CompatibleDifferent mechanisms of action. 5-Amino-1MQ inhibits NNMT for metabolic effects while orforglipron acts on GLP-1R. No known interactions.
Semaglutide
CautionBoth are GLP-1 receptor agonists. Concurrent use would result in redundant mechanisms and increased risk of GI side effects. Not recommended to combine.
BPC-157
CautionBoth affect GI function. BPC-157 is gastroprotective while orforglipron slows gastric emptying. Monitor GI symptoms if combined.
Tirzepatide
AvoidTirzepatide is a dual GIP/GLP-1 agonist. Combining with orforglipron would cause overlapping GLP-1 receptor activation. Contraindicated.
Retatrutide
AvoidRetatrutide is a triple GIP/GLP-1/glucagon agonist. Concurrent GLP-1 receptor activation contraindicated.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Orforglipron
Orforglipron Calculators
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.